MYREXIS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2020-11-05: Study NCT04396808; Company role Collaborator; Phase Not applicable; Status Active not recruiting.
- 2010-12: Study NCT01285414; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2009-11: Study NCT01026727; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2009-06: Study NCT00920205; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2020-11-05 | NCT04396808 Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | Collaborator Lead: University of Michigan Rogel Cancer Center | Not applicable | Active not recruiting | Prostate Cancer | 805 | 2031-03 |
| 2010-12 | NCT01285414 Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme | Lead sponsor | Phase 2 | Completed | Glioblastoma Multiforme | 5 | 2012-03 |
| 2009-11 | NCT01026727 A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy | Lead sponsor | Phase 2 | Terminated | HIV Infections | 2 | 2010-06 |
| 2009-06 | NCT00920205 Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments | Lead sponsor | Phase 1 | Completed | Cancer | 26 | 2011-06 |
| 2009-04 | NCT00892931 Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme | Lead sponsor | Phase 2 | Completed | Glioblastoma Multiforme | 56 | 2011-09 |
| 2008-11 | NCT01097070 A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days | Lead sponsor | Phase 2 | Completed | HIV-1 Infection | 35 | 2009-01 |
| 2008-05 | NCT00967187 Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection. | Lead sponsor | Phase 2 | Completed | HIV Infections | 32 | 2009-12 |
| 2008-03 | NCT00635557 Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | Lead sponsor | Phase 1, Phase 2 | Unknown | Glioblastoma Multiforme | 30 | 2011-08 |
| 2008-03 | NCT00609011 Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma | Lead sponsor | Phase 1, Phase 2 | Completed | Metastatic Melanoma | 22 | 2009-08 |
| 2007-05-23 | NCT00478686 Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine | Collaborator Lead: M.D. Anderson Cancer Center | Observational | Completed | Breast Cancer | 102 | 2017-05-02 |
| 2006-09 | NCT00380276 Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol | Lead sponsor | Phase 3 | Terminated | Alzheimer's Disease | 1,000 | 2008-12 |
| 2006-05 | NCT00322036 Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's | Lead sponsor | Phase 3 | Terminated | Alzheimer Disease; Dementia | 800 | 2008-12 |
| 2006-04 | NCT00511368 Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks* | Lead sponsor | Phase 2 | Completed | HIV Infections | 92 | 2008-07 |
| 2005-12 | NCT00393965 Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases | Lead sponsor | Phase 1 | Completed | Brain Neoplasms | 18 | 2008-02 |
| 2005-03 | NCT00394446 Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors | Lead sponsor | Phase 1 | Completed | Refractory Solid Tumors | 48 | 2008-02 |
| 2005-02 | NCT00105547 Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's | Lead sponsor | Phase 3 | Completed | Alzheimer Disease; Dementia | 1,600 | 2008-05 |
| 2002-02 | NCT00045123 R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence | Lead sponsor | Phase 2 | Unknown | Prostate Cancer |